Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.
The group goes after a KRAS-related target on which Boehringer recently gave up.
Conferences ramp up, and ASH abstracts near.
Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.
AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.
